abstract：:Desmoplastic small round cell tumor (DSRCT) is a rare and aggressive malignancy with poor outcome occurring in adolescents and young adults. Therapeutic options for patients with advanced disease are limited. Preclinical studies have shown that VEGFR-2 and VEGFA are overexpressed in DSRCT and that DSRCT xenografts wer...

journal_title：Targeted oncology

authors： Italiano A,Kind M,Cioffi A,Maki RG,Bui B

更新日期：2013-09-01 00:00:00

abstract：:The currently prevalent somatic mutation theory of carcinogenesis and metastases explicitly assumes that cancer is a cellular disease, i.e. a disease of the control of cell proliferation and/or cell differentiation. Accordingly, explanations should always be sought for at a gene and/or gene product level, regardless o...

journal_title：Targeted oncology

authors： Demicheli R

更新日期：2013-06-01 00:00:00

abstract：:Non-small cell lung cancer (NSCLC) has recently been associated with interesting molecular characteristics that have important implications in carcinogenesis and response to targeted therapies. Targeted therapies, if given to a patient subpopulation enriched by the presence of relevant molecular targets, can often abr...

journal_title：Targeted oncology

authors： Planchard D

更新日期：2013-03-01 00:00:00

abstract：:Personalized medicine is defined by the National Cancer Institute as "a form of medicine that uses information about a person's genes, proteins, and environment to prevent, diagnose, and treat disease." In oncology, the term "personalized medicine" arose with the emergence of molecularly targeted agents. The prescript...

journal_title：Targeted oncology

authors： Le Tourneau C,Kamal M,Trédan O,Delord JP,Campone M,Goncalves A,Isambert N,Conroy T,Gentien D,Vincent-Salomon A,Pouliquen AL,Servant N,Stern MH,Le Corroller AG,Armanet S,Rio Frio T,Paoletti X

更新日期：2012-12-01 00:00:00

abstract：:The advent of imatinib mesilate, an oral target therapy, has dramatically changed the natural history of gastrointestinal stromal tumours (GISTs). This rare neoplasm has become the paradigm of targeted therapies in solid tumours, also introducing a home-based cure concept in oncology. However, it should be retained th...

journal_title：Targeted oncology

authors： Saponara M,Pantaleo MA,Nannini M,Biasco G

更新日期：2012-12-01 00:00:00

abstract：:Hypoxia is a critical hallmark of solid tumors and involves enhanced cell survival, angiogenesis, glycolytic metabolism, and metastasis. Hyperbaric oxygen (HBO) treatment has for centuries been used to improve or cure disorders involving hypoxia and ischemia, by enhancing the amount of dissolved oxygen in the plasma a...

journal_title：Targeted oncology

authors： Moen I,Stuhr LE

更新日期：2012-12-01 00:00:00

abstract：:Among neuroendocrine carcinomas of the gut, well-differentiated tumors are highly vascularized, featuring specific characteristics on contrast-enhanced imaging. Well-differentiated neuroendocrine tumors spontaneously harbor hypervascular enhancement, coexisting with areas of necrosis mainly located at the center of tu...

journal_title：Targeted oncology

authors： Faivre S,Ronot M,Dreyer C,Serrate C,Hentic O,Bouattour M,Bruno O,Couvelard A,Vilgrain V,Raymond E

更新日期：2012-06-01 00:00:00

abstract：:Posterior reversible encephalopathy syndrome (PRES) is a clinico-radiological entity that may occur in patients receiving anti-vascular endothelial growth factor (VEGF) agents such as bevacizumab and tyrosine kinase inhibitors. Little is known about the characteristics of patients at risk for PRES under anti-VEGF agen...

journal_title：Targeted oncology

authors： Tlemsani C,Mir O,Boudou-Rouquette P,Huillard O,Maley K,Ropert S,Coriat R,Goldwasser F

更新日期：2011-12-01 00:00:00

abstract：:The ubiquitin (Ub)+proteasome proteolytic pathway is responsible for the selective degradation of the majority of nuclear and cytosolic proteins. The proteasome is a high molecular weight multicatalytic protease that serves as the catalytic core of the complex Ub-dependent protein degradation pathway and is an excitin...

journal_title：Targeted oncology

authors： Driscoll JJ,Dechowdhury R

更新日期：2010-12-01 00:00:00

abstract：:Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Efficacy of this drug was documented in the BR.21 trial showing that adenocarcinoma, female gender, Asian ethnicity and never-smoker status are predictive of clinical response to erlotinib. Retrospective studies documented the same bene...

journal_title：Targeted oncology

authors： Rossi D,Dennetta D,Ugolini M,Catalano V,Alessandroni P,Giordani P,Baldelli AM,Casadei V,Graziano F,Luzi Fedeli S

更新日期：2010-12-01 00:00:00

abstract：:Dynamic contrast-enhanced ultrasonography (DCE-US) is a new functional technique enabling a quantitative assessment of solid tumor perfusion using raw linear data. DCE-US allows the calculation of parameters as slope of wash-in or area under the curve (AUC) representing, respectively, blood flow or blood volume. Reduc...

journal_title：Targeted oncology

authors： Lassau N,Chebil M,Chami L,Bidault S,Girard E,Roche A

更新日期：2010-03-01 00:00:00

abstract：:Chemotherapy represents the mainstay of non-small cell lung cancer (NSCLC) treatment, but response is usually observed in only one out of three patients. Massive efforts have been carried out to identify biomarkers that might help clinicians to choose appropriate drugs, by identifying potentially sensitive subjects an...

journal_title：Targeted oncology

authors： Toschi L,Cappuzzo F

更新日期：2010-03-01 00:00:00

abstract：:It is believed that the insulin-like growth factor receptor type 1 (IGF-1R) signaling pathway plays a pivotal role in cancer growth, progression, and resistance to anticancer therapies. Strategies are being developed to block IGF-1R as an anticancer treatment. We reviewed several potential strategies for disrupting th...

journal_title：Targeted oncology

authors： Atzori F,Traina TA,Ionta MT,Massidda B

更新日期：2009-12-01 00:00:00

abstract：:Differentiated thyroid carcinoma is the most frequent neoplasm of the endocrine system. Although thyroid cancer usually has an excellent prognosis, no therapeutic options are available for patients that develop metastases and are or became resistant to radioiodine therapy. The deeper knowledge of molecular aberrations...

journal_title：Targeted oncology

authors： Capdevila J,Perez-Garcia J,Obiols G,Tabernero J

更新日期：2009-12-01 00:00:00

abstract：:Several angiogenesis inhibitors have been approved for commercial use and many additional agents are under development for the treatment of various malignancies. Cardiovascular toxicities have been increasingly recognized as effects of this entire class of new anticancer therapeutics. There is a limited but growing un...

journal_title：Targeted oncology

authors： Snider KL,Maitland ML

更新日期：2009-04-01 00:00:00

abstract：:Elderly and poor performance status advanced non-small cell lung cancer (NSCLC) patients often tolerate chemotherapy poorly. Special approaches are needed for these patient populations. Tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor (EGFR), erlotinib and gefitinib, are active agents in the t...

journal_title：Targeted oncology

authors： Lin CC,Yang CH

更新日期：2009-01-01 00:00:00